stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) EV/EBITDA
As of 5 November 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a EV/EBITDA of 17.8×. Over the past ten years it has ranged from 0.0× (September 2025) to 256× (August 2024); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 91.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 29.5× | (18.04%) |
| Jun 2026 | 36.0× | (30.86%) |
| Mar 2026 | 52.0× | (42.81%) |
| Dec 2025 | 91.0× | (49.88%) |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 15.2× |
| EXEL Exelixis, Inc. compare | 15.6× |
| ALNY Alnylam Pharmaceuticals, Inc. | 17.8× |
| INCY Incyte Corporation compare | 27.9× |
| ASND Ascendis Pharma A/S compare | 49.5× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement